Web Survey of Society Members' Recognition of Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea, 2013 Revised Edition.
10.7704/kjhugr.2015.15.2.95
- Author:
Hyun Joo SONG
1
;
Ki Nam SHIM
;
Byung Wook KIM
Author Information
1. Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
- Publication Type:Original Article
- Keywords:
Helicobacter pylori;
Guideline;
Internet;
Data collection;
Societies
- MeSH:
Anti-Bacterial Agents;
Surveys and Questionnaires;
Diagnosis*;
Electronic Mail;
Female;
Gastritis, Atrophic;
Helicobacter pylori*;
Humans;
Internet;
Korea;
Lymphoma, B-Cell, Marginal Zone;
Male;
Mass Screening;
Peptic Ulcer;
Stomach Neoplasms
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2015;15(2):95-102
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: We aimed to evaluate recognition of the 2013 revised guidelines for diagnosis and treatment of Helicobacter pylori infection in Korea by members of the society through a web survey. MATERIALS AND METHODS: We analyzed the respondents' agreement with the 19 guidelines in terms of awareness and adherence. Among 718 physicians, 149 (20.8%) answered the questionnaire by e-mail between October and November 2013. RESULTS: The mean age of the respondents was 40+/-7 years, and the ratio of men to women were 74.5:25.5. The respondents were as follows: professors (36.2%), fellows (31.5%), salaried doctors (17.4%), private practitioners (11.4%), and screening center clinicians (3.4%). Among the 141 respondents, 69.1% had read, 17.3% agreed completely, and 77.3% agreed generally with the guidelines. The respondents indications for eradication were peptic ulcer disease (77.2%), MALT lymphoma (89.3%), and following endoscopic therapy for early gastric cancer (71.1%). However, 42.3% and 48.3% of the physicians administered H. pylori eradication treatment for patients with atrophic gastritis and a family history of gastric cancer, respectively. Triple therapy as first line regimens was administered by 81.2% of the respondents. The duration was one-week for 77.7% and two-weeks for 13.4%. A total of 55.7% prescribed a bismuth-based secondary treatment. When bismuth-based initial therapy failed, a combination of 2 antibiotics that were not used as first-line therapy were used (37.6%). CONCLUSIONS: This web survey was very helpful for analyzing society members' recognition of 2013 revised guidelines. Generally, all the society members followed the guidelines.
